To investigate for the risk of uveitis among such patients. A retrospective cohort study utilized the TriNetX database and recruited pediatric autoimmune patients diagnosed between January 1st 2004 and December 31st 2022. The non-autoimmune cohort were randomly selected control patients matched by sex, age, and index year.
View Article and Find Full Text PDFObjective: Endometrial cancer (EC) is a common gynecological malignancy, and its metastasis is one of the primary causes of treatment failure. Immunoglobulin superfamily member 1 (IGSF1), a membrane protein, has been associated with the aggressiveness and metastatic capability of various cancers. However, the role and mechanism of this protein in EC remains unclear.
View Article and Find Full Text PDFJ Am Acad Dermatol
December 2024
Background: The risk of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) in patients with psoriatic disease receiving biologics is not fully understood.
Objective: This study aimed to investigate whether novel biologic therapies (IL-17, IL-12/23, and IL-23 inhibitors) for biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) are associated with differences in the risks of MACE and VTE compared with those with TNF inhibitors.
Methods: An emulated target trial was designed by a nationwide cohort using data from the TriNetX Research Network.
J Colloid Interface Sci
December 2024
Photocatalytic removal of antibiotic such as ciprofloxacin from polluted water is of great value for eco-environment protection. To further enhance the piezoelectric effect in photocatalysis, we designed and synthesized a ternary heterojunction piezoelectric photocatalyst through uniformly loading MoS nanosheets onto BiFeO (BFO) nanofibers, namely MoS/BiS/BFO. Piezoresponse force microscopy and Kelvin probe force microscopy demonstrated its enhanced piezoelectric properties, showing a maximum amplitude displacement of 395.
View Article and Find Full Text PDFCAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.
View Article and Find Full Text PDF